SCHEMBL468901

SCHEMBL468901

CC(=O)NC(CCCNC(=N)N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.49
GNPAT O15228 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
NFKB1 P19838 1/20 0.44
PTGS2 P35354 1/20 0.44
THPO P40225 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
ALB P02768 3/20 0.44
SIRT6 Q8N6T7 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SIRT5 Q9NXA8 3/20 0.42
C3AR1 Q16581 1/20 0.40
NOD1 Q9Y239 2/20 0.39
CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6026003 1.00 FOLH1 (0.49) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL30526285 1.00 FOLH1 (0.49) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL446929 1.00 FOLH1 (0.49) FOLH1GNPATSMN1; SMN2KDM4EMAPT
Acetic Acid SCHEMBL28406175 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL9438405 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
Water SCHEMBL29401510 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
Hydrochloric Acid SCHEMBL4422480 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL468736 0.95 FOLH1 (0.55) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL22769501 0.95 FOLH1 (0.55) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL29550463 0.95 FOLH1 (0.55) FOLH1GNPATSMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615069-B1 N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES AMGEN INC (US) 2025-05-28 EP claimed
EP-4537111-A2 MULTI-OMICS ASSESSMENT Prognomiq Inc (US) 2025-04-16 EP claimed
CN-119816897-A Multiple study assessment 普罗科技有限公司 2025-04-11 CN claimed
US-12103979-B2 N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides AMGEN INC. (US) 2024-10-01 US claimed
WO-2023240046-A2 MULTI-OMICS ASSESSMENT PrognomIQ, Inc. (US) 2023-12-14 WO claimed
US-11833127-B2 Compositions and methods for the treatment of fat infiltration in muscle AXCELLA HEALTH INC. (US) 2023-12-05 US claimed
CN-116898955-A Liquid pharmaceutical composition containing teriparatide with excellent stability 旭化成制药株式会社 2023-10-20 CN claimed
US-20230038163-A1 AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF POST-ACUTE SEQUELAE OF COVID-19 AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC 2023-02-09 US claimed
WO-2022266480-A1 METHODS OF PREDICTING LIVER FAT CONTENT AND USES THEREOF AXCELLA HEALTH INC. (US) 2022-12-22 WO claimed
US-11129804-B2 Amino acid compositions and methods for the treatment of liver diseases AXCELLA HEALTH INC. (US) 2021-09-28 US claimed
US-6951842-B2 Compositions providing for increased IGF-I solubility CHIRON CORPORATION (US) 2005-10-04 US claimed
EP-1570840-A2 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2005-09-07 EP claimed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 US claimed
US-20040209815-A1 Compositions providing for increased IGF-I solubility CHIRON CORPORATION 2004-10-21 US claimed
US-6767892-B1 INSULIN-LIKE GROWTH FACTOR-1 IS SOLUBILIZED WITH GUANIDINIUM COMPOUND CHRION CORPORATION 2004-07-27 US claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
EP-0673432-B1 PROCESS FOR PREPARING CLAVULANIC ACID SMITHKLINE BEECHAM PLC (GB) 1999-03-24 EP claimed
EP-0736770-A2 An immunoreactive conjugate, method for its preparation, antibodies to said conjugate and a pharmaceutical composition and diagnostic device containing them ANDA BIOLOGICALS S.A. (FR) 1996-10-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12103979-B2 N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides ARGLU1, PNISR, DNPEP FOLH1 140/4885GNPAT 1820/4885SMN1; SMN2 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.